INBXInhibrx Biosciences, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $1M
- 550% YoY
- Operating margin
- -10386.5%
- 94% YoY
- EBITDA
- −$133M
- 60% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $43M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired857% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $2M | $200K | $1M | 550% |
| Operating income | −$219M | −$331M | −$135M | 59% |
| Net income | −$241M | $1.7B | −$140M | 108% |
| Operating cash flow | −$193M | −$194M | −$130M | 33% |
| Capex | $5M | $3M | $31K | 99% |
| Stock-based comp | $25M | $59M | $11M | 81% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $6M · 20
- Open-market sells, 12 mo
- $279K · 5
- Net
- $6M
Pay vs performance
No pay-versus-performance disclosure yet.